Remdesivir powers, activate! Surya Singh

Wouldn’t it be great if remdesivir magically cured COVID-19? Too bad it doesn’t. So what should we be willing to pay for a drug that shortens hospital stays and might reduce mortality? In this episode of HealthBiz, physician and healthcare executive Surya Singh shares his take on drug pricing, ICER and the future of the pandemic. 

Check out the links.

• Surya’s LinkedIn profile https://www.linkedin.com/in/surya-singh-8540032/ 
• Institute for Clinical and Economic Review (ICER) remdesivir pricing model https://icer-review.org/announcements/alternative_pricing_models_for_remdesivir/ 
• Letter from State Attorneys General about remdesivir pricing https://patreasury.gov/pdf/newsroom/Gilead-Sciences-Letter_Redacted.pdf 
• Boston Globe article comparing MA and RI school reopening plans https://www.bostonglobe.com/2020/09/18/metro/how-rhode-island-brought-most-students-back-in-person-learning-massachusetts-did-not/ 
• Remdesivir https://www.gilead.com/remdesivir 
• Inspiration for “Remdesivir powers, activate!” https://youtu.be/FouDjI3GzEI 
• David’s LinkedIn profile https://www.linkedin.com/in/davideugenewilliams/ 
• Health Business Group https://healthbusinessgroup.com/ 

Host David E. Williams is president of healthcare strategy consulting firm Health Business Group. Produced by Dafna Williams.